Drug Profile
JNJ 17166864
Latest Information Update: 30 Sep 2015
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Antiallergics; Small molecules
- Mechanism of Action CCR2 receptor antagonists; Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Seasonal allergic rhinitis
Most Recent Events
- 30 Sep 2015 No recent reports on development identified - Phase-I/II for Seasonal allergic rhinitis in USA (Intranasal)
- 30 Sep 2015 No recent reports on development identified - Preclinical for Inflammation in USA (Topical)
- 21 May 2008 Preclinical trials in Inflammation in USA (Topical)